GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theriva Biologics Inc (AMEX:TOVX) » Definitions » Operating Margin %

Theriva Biologics (Theriva Biologics) Operating Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Theriva Biologics Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Theriva Biologics's Operating Income for the three months ended in Dec. 2023 was $-6.22 Mil. Theriva Biologics's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Theriva Biologics's Operating Margin % for the quarter that ended in Dec. 2023 was 0.00%.

The historical rank and industry rank for Theriva Biologics's Operating Margin % or its related term are showing as below:


TOVX's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -172
* Ranked among companies with meaningful Operating Margin % only.

Theriva Biologics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Theriva Biologics's Operating Income for the three months ended in Dec. 2023 was $-6.22 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-21.43 Mil.


Theriva Biologics Operating Margin % Historical Data

The historical data trend for Theriva Biologics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theriva Biologics Operating Margin % Chart

Theriva Biologics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Theriva Biologics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Theriva Biologics's Operating Margin %

For the Biotechnology subindustry, Theriva Biologics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theriva Biologics's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theriva Biologics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Theriva Biologics's Operating Margin % falls into.



Theriva Biologics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Theriva Biologics's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-21.431 / 0
= %

Theriva Biologics's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-6.217 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Theriva Biologics  (AMEX:TOVX) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Theriva Biologics Operating Margin % Related Terms

Thank you for viewing the detailed overview of Theriva Biologics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Theriva Biologics (Theriva Biologics) Business Description

Traded in Other Exchanges
Address
9605 Medical Center Drive, Suite 270, Rockville, MD, USA, 20850
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11, leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
Executives
Steven A Shallcross director, officer: CEO and CFO C/O ELYS GAME TECHNOLOGY CORP., 130 ADELAIDE STREET WEST, SUITE 701, TORONTO A6 M5H2K4
Francis Tufaro officer: Chief Operating Officer 9605 MEDICAL CENTER DRIVE SUITE 270, ROCKVILLE MD 20850
John J Monahan director
Scott Tarriff director 28 TUDOR ROSE TERRACE, MAHWAH NJ 07430
Randal J Kirk 10 percent owner 1881 GROVE AVENUE, RADFORD VA 24141
Joseph A. Sliman officer: CHIEF MEDICAL OFFICER 9605 MEDICAL CENTER DRIVE, SUITE 270, ROCKVILLE MD 20850
Jeffrey Scott Riley director C/O ADEONA PHARMACEUTICALS, INC, 3930 VARSITY DRIVE, ANN ARBOR MI 48108
Intrexon Corp 10 percent owner 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Charles Evan Ballantyne officer: CHIEF FINANCIAL OFFICER 27 HEARTHSTONE ROAD, HOPKINTON MA 01748
Nelson K. Stacks director C/O ADEONA PHARMACEUTICALS, INC., 3985 RESEARCH PARK DRIVE, SUITE 200, ANN ARBOR MI 48108
Lyon Lyman Max Jr director, officer: CEO & President C/O ADEONA PHARMACEUTICALS, 3930 VARSITY DRIVE, ANN ARBOR MI 48108
David A. Newsome officer: Chief Scientific Officer 3930 VARSITY DRIVE, C/O PIPEX PHARMACEUTICALS, INC., ANN ARBOR MI 48108
James S Kuo director 509 MADISON AVE 14TH FL, NEW YORK NY 10022
Daniel J Dorman director
Wayne George Holman 10 percent owner 430 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022

Theriva Biologics (Theriva Biologics) Headlines

From GuruFocus